Home › Glioblastoma › NCT06059690

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Biologic Association Between Metabolic MR-PET and Tissue Measures of Glycolysis in Brain Tumors Visualization, Quantitation, and Targeting of Infiltrating Glioblastoma Cells With pH Sensitive Amine Chemical Exchange Saturation Transfer Magnetic Resonance Imaging-KL2TR001882

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age \> 18
* Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery

Exclusion Criteria:

* Patients who cannot obtain an MRI or FDG PET scan with contrast
* Those with ferromagnetic implanted devices that might produce a safety hazard (e.g. infusion pumps, pace makers, aneurysm clips, etc.) will be excluded from the study along with subjects with severe claustrophobia or who have severely compromised renal function (GFR \< 30).

About the study

The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Investigators will then correlate the imaging measurements with pH, RNA expression, protein expression, and bioenergetics measurements of key glycolytic enzymes.

What is being tested

• pH Measurement of in vivo tissue (diagnostic test)

Sponsor: Jonsson Comprehensive Cancer Center · Participants: 50 · Started: Sep 6, 2023

Contact the study team

• Raksha Nagaraj · Phone: 310-794-8995
• Saima Chaabane · Phone: 310-794-8995

Official record on ClinicalTrials.gov — NCT06059690

Locations in the U.S.

Conditions

• Glioblastoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.